Statistics

Total Visits

Views
Phase 2 Randomized, Noncomparative, Open-Label Study of Aflibercept and Modified Folfox6 in the First-Line Treatment of Metastatic Colorectal Cancer (Affirm)6

Select a period of time:

Number of views in the range

Views
Phase 2 Randomized, Noncomparative, Open-Label Study of Aflibercept and Modified Folfox6 in the First-Line Treatment of Metastatic Colorectal Cancer (Affirm)4

Views

Views
May 20240
June 20243
July 20241
August 20240
September 20240
October 20240
November 20240
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States4
 

Top cities views

Views
Chicago1